Absci Corp
NASDAQ:ABSI

Watchlist Manager
Absci Corp Logo
Absci Corp
NASDAQ:ABSI
Watchlist
Price: 2.56 USD 0.39% Market Closed
Market Cap: 290.7m USD
Have any thoughts about
Absci Corp?
Write Note

Absci Corp
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Absci Corp
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Absci Corp
NASDAQ:ABSI
Cash from Operating Activities
-$64.6m
CAGR 3-Years
-81%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Cash from Operating Activities
$9.1B
CAGR 3-Years
-4%
CAGR 5-Years
13%
CAGR 10-Years
14%
Danaher Corp
NYSE:DHR
Cash from Operating Activities
$6.3B
CAGR 3-Years
-9%
CAGR 5-Years
9%
CAGR 10-Years
6%
Mettler-Toledo International Inc
NYSE:MTD
Cash from Operating Activities
$983.6m
CAGR 3-Years
2%
CAGR 5-Years
10%
CAGR 10-Years
10%
Agilent Technologies Inc
NYSE:A
Cash from Operating Activities
$1.8B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
7%
IQVIA Holdings Inc
NYSE:IQV
Cash from Operating Activities
$2.6B
CAGR 3-Years
-5%
CAGR 5-Years
16%
CAGR 10-Years
21%
No Stocks Found

Absci Corp
Glance View

Market Cap
292.3m USD
Industry
Life Sciences Tools & Services

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 216 full-time employees. The company went IPO on 2021-07-22. The firm has developed an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The company uses synthetic biology technologies and deep learning artificial intelligence (AI) to predict, identify, design, construct, screen, select and scale production of biologic drug candidates, and learn from the data it generates. The firm has drug candidates in approximately nine active programs, eight of the active programs are focused on developing production cell lines for drug candidates that the Company's partners are developing. The company has one discovery program, focused on lead optimization with Astellas. The Company’s active programs include Bispecific monoclonal antibodies (mAb), Bispecific T-cell engager, Cytokine, Fab, Multivalent Fc-fusion, Plasma protein and mAb.

ABSI Intrinsic Value
1.45 USD
Overvaluation 43%
Intrinsic Value
Price

See Also

What is Absci Corp's Cash from Operating Activities?
Cash from Operating Activities
-64.6m USD

Based on the financial report for Dec 31, 2023, Absci Corp's Cash from Operating Activities amounts to -64.6m USD.

What is Absci Corp's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-81%

Over the last year, the Cash from Operating Activities growth was 21%. The average annual Cash from Operating Activities growth rates for Absci Corp have been -81% over the past three years .

Back to Top